$SPHS MVP big Board Contest Nasdaq Upturn $2.34
Post# of 20
Posted On: 01/23/2016 11:41:21 AM
$SPHS MVP big Board Contest Nasdaq
Upturn $2.34
Website
Sophiris Bio Inc.
Potential FDA Decision Around the Corner
Brief ReportAccesswire(Tue, Jan 5)
Shares Outstanding: 16.84M
Float: 14.19M
% Held by Insiders: 7.85%
% Held by Institution1: 5.50%
Shares Short (as of Dec 31, 2015): 338.69K
Short Ratio (as of Dec 31, 2015): 0.98
Short % of Float (as of Dec 31, 2015): 2.27%
Shares Short (prior month): 218.42K
Headlines
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The companys primary product candidate is PRX302, which is in Phase III clinical trial for treatment for the symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Upturn $2.34
Website
Sophiris Bio Inc.
Potential FDA Decision Around the Corner
Brief ReportAccesswire(Tue, Jan 5)
Shares Outstanding: 16.84M
Float: 14.19M
% Held by Insiders: 7.85%
% Held by Institution1: 5.50%
Shares Short (as of Dec 31, 2015): 338.69K
Short Ratio (as of Dec 31, 2015): 0.98
Short % of Float (as of Dec 31, 2015): 2.27%
Shares Short (prior month): 218.42K
Headlines
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The companys primary product candidate is PRX302, which is in Phase III clinical trial for treatment for the symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
(0)
(0)Sophiris Bio Inc. (SPHS) Stock Research Links
Scroll down for more posts ▼